Scribe Therapeutics, Inc. IPO
listed
| Exchange | Nasdaq |
| Ticker | SCTX |
| Price range | $13–15 |
| IPO price | $15 |
| Deal size | $129m |
| First-day close | $21.65 (+44.3%) |
| First trading day | 24 Jul 2026 |
| First filing seen | 10 Jul 2026 |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Alameda, CA |
| Incorporated in | DE |
Upsized; 8.6 million shares at the high end of the $13-$15 range, 1.4 million more than planned. Phase 1 CRISPR biotech. Source does not say if size includes over-allotment.
SEC filings
| Form | What it is | Filed |
|---|---|---|
| S-1/A | Amended registration statement | 20 Jul 2026 |
| S-1/A | Amended registration statement | 10 Jul 2026 |
Deal terms: Renaissance Capital ↗ · Filings: SEC EDGAR ↗
This page reports public filings and reported deal terms. It is not a recommendation to buy, sell or apply.